PD-1 blockade in Japanese patients with acral lentiginous melanoma
- PMID: 32622883
- DOI: 10.1016/j.annonc.2020.06.014
PD-1 blockade in Japanese patients with acral lentiginous melanoma
Conflict of interest statement
Disclosure ANS serves on advisory board for BMS, Immunocore, Castle Biosciences and receives institutional research funding from Bristol-Myers Squibb, Immunocore, Xcovery, Polaris.
Comment on
-
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.Ann Oncol. 2020 Sep;31(9):1198-1206. doi: 10.1016/j.annonc.2020.05.031. Epub 2020 Jun 6. Ann Oncol. 2020. PMID: 32522691
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical